GeoVax to Participate in Upcoming Investor Conferences in September
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company focused on developing immunotherapies and vaccines, has announced its participation in two upcoming investor conferences in September 2024. Chairman and CEO David Dodd will present at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET in New York, NY.
2. Emerging Growth Conference on September 25, 2024, at 2:55 p.m. ET, which will be held virtually.
Both presentations will provide corporate updates on GeoVax. At the H.C. Wainwright conference, senior management will also host one-on-one meetings with registered attendees. Interested parties can contact GeoVax directly at info@geovax.com to arrange meetings.
GeoVax Labs, Inc. (Nasdaq: GOVX), una società biotecnologica focalizzata sullo sviluppo di immunoterapie e vaccini, ha annunciato la sua partecipazione a due imminenti conferenze per investitori a settembre 2024. Il presidente e CEO David Dodd presenterà entrambi gli eventi:
1. H.C. Wainwright 26a Conferenza Globale annuale sugli Investimenti il 9 settembre 2024, alle 7:00 a.m. ET a New York, NY.
2. Conferenza sulle Crescite Emergenti il 25 settembre 2024, alle 2:55 p.m. ET, che si terrà in forma virtuale.
Entrambe le presentazioni forniranno aggiornamenti aziendali su GeoVax. Durante la conferenza H.C. Wainwright, la direzione senior organizzerà anche incontri one-on-one con i partecipanti registrati. Le parti interessate possono contattare direttamente GeoVax all'indirizzo info@geovax.com per organizzare incontri.
GeoVax Labs, Inc. (Nasdaq: GOVX), una empresa biotecnológica enfocada en el desarrollo de inmunoterapias y vacunas, ha anunciado su participación en dos próximas conferencias de inversores en septiembre de 2024. El presidente y CEO David Dodd presentará en ambos eventos:
1. H.C. Wainwright 26ª Conferencia Anual Global de Inversiones el 9 de septiembre de 2024, a las 7:00 a.m. ET en Nueva York, NY.
2. Conferencia de Crecimiento Emergente el 25 de septiembre de 2024, a las 2:55 p.m. ET, que se llevará a cabo de forma virtual.
Ambas presentaciones proporcionarán actualizaciones corporativas sobre GeoVax. En la conferencia H.C. Wainwright, la alta dirección también realizará reuniones uno a uno con los asistentes registrados. Las partes interesadas pueden contactar directamente a GeoVax a info@geovax.com para concertar reuniones.
GeoVax Labs, Inc. (Nasdaq: GOVX), 면역 요법 및 백신 개발에 중점을 둔 생명공학 회사가 2024년 9월에 있을 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회장 겸 CEO 데이비드 도드가 두 행사 모두에서 발표할 예정입니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 회의가 2024년 9월 9일 오전 7시에 뉴욕, NY에서 열립니다.
2. 신흥 성장 회의가 2024년 9월 25일 오후 2시 55분에 온라인으로 진행됩니다.
두 프레젠테이션 모두 GeoVax에 대한 기업 업데이트를 제공할 것입니다. H.C. Wainwright 회의에서는 고위 경영진이 등록된 참석자들과 일대일 회의를 개최합니다. 관심 있는 분들은 회의를 주선하기 위해 info@geovax.com으로 GeoVax에 직접 연락할 수 있습니다.
GeoVax Labs, Inc. (Nasdaq: GOVX), une entreprise biopharmaceutique spécialisée dans le développement d'immunothérapies et de vaccins, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. Le président et CEO David Dodd présentera lors des deux événements :
1. 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright le 9 septembre 2024, à 7h00 ET à New York, NY.
2. Conférence sur la Croissance Émergente le 25 septembre 2024, à 14h55 ET, qui se tiendra virtuellement.
Les deux présentations fourniront des mises à jour sur l'entreprise GeoVax. Lors de la conférence H.C. Wainwright, la direction senior organisera également des réunions individuelles avec les participants inscrits. Les parties intéressées peuvent contacter directement GeoVax à l'adresse info@geovax.com pour organiser des réunions.
GeoVax Labs, Inc. (Nasdaq: GOVX), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von Immuntherapien und Impfstoffen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. Vorsitzender und CEO David Dodd wird auf beiden Veranstaltungen präsentieren:
1. H.C. Wainwright 26. jährliche globale Investorenkonferenz am 9. September 2024 um 7:00 Uhr ET in New York, NY.
2. Konferenz für aufstrebendes Wachstum am 25. September 2024 um 14:55 Uhr ET, die virtuell stattfinden wird.
Beide Präsentationen bieten Unternehmensupdates zu GeoVax. Auf der H.C. Wainwright-Konferenz wird das obere Management auch Einzelgespräche mit registrierten Teilnehmern führen. Interessierte Parteien können GeoVax direkt unter info@geovax.com kontaktieren, um Meetings zu vereinbaren.
- None.
- None.
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events:
| H.C. Wainwright 26th Annual Global Investment Conference | ||
| Speaker: | David Dodd, Chairman & CEO | |
| Date/Time: | September 9, 2024 at 7:00 a.m. ET | |
| Location: | Lotte New York Palace Hotel, New York, NY | |
| Webcast Link: | H.C. Wainwright Webcast | |
| Title: | GeoVax Corporate Update | |
Senior GeoVax management will host one-on-one meetings with registered attendees. If interested in meeting with management at this event, please contact the company through the conference portal, or directly at info@geovax.com.
| Emerging Growth Conference | ||
| Speaker: | David Dodd, Chairman & CEO | |
| Date/Time: | September 25, 2024 at 2:55 p.m. ET | |
| Location: | Virtual | |
| Webcast Link: | Emerging Growth Conference Webcast | |
| Title: | GeoVax Corporate Update | |
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
When and where will GeoVax (GOVX) present at the H.C. Wainwright Global Investment Conference in September 2024?
What is the date and time for GeoVax's (GOVX) presentation at the Emerging Growth Conference in September 2024?
Who will be presenting on behalf of GeoVax (GOVX) at the September 2024 investor conferences?
How can investors arrange one-on-one meetings with GeoVax (GOVX) management at the H.C. Wainwright conference?
